At-Home Brain Stimulation Treatment Can Safely Ease Depression
By Dennis Thompson HealthDay Reporter
TUESDAY, Oct. 22, 2024 -- At-home brain stimulation therapy can safely and effectively treat severe to moderate depression, a new clinical trial shows.
Rates of treatment response and depression remission were three times higher in people receiving the noninvasive brain stimulation, researchers said.
“The study results bring promise that an innovative treatment modality may become available for patients suffering from mood disorders some time in the near future,” said co-lead researcher Dr. Jaire Soares, chair of psychiatry with the University of Texas McGovern Medical School.
For the study, 174 people diagnosed with depression were randomly assigned to receive or forego brain stimulation during a 10-week course of treatment.
Those receiving brain stimulation got five 30-minute sessions a week for the first three weeks, followed by three 30-minute sessions a week for the next seven weeks.
The therapy is called transcranial direct current stimulation (tDCS), in which a current of between 0.5 to 2 milliampere is applied to the scalp through two electrodes. This amount of electricity causes at most a slight tingling sensation along the scalp.
The stimulation was self-administered by patients in their own homes, researchers said.
About 45% of people receiving the stimulation wound up with their depression in remission, compared with 22% of the control group, researchers found.
“The burden of depression is mostly keenly felt by the 280 million people worldwide currently managing symptoms. While a combination of antidepressants and therapy generally proves to be effective for many people, medication can have side effects that some can find disruptive,” said senior researcher Dr. Cynthia Fu, a professor of affective neuroscience and psychotherapy at King’s College London.
“Our study has demonstrated that tDCS is a potential first-line option that could help those in need,” Fu added in a University of Texas news release.
The study was funded by Flow Neuroscience, the manufacturer of the stimulation device.
The study was published Oct. 21 in the journal Nature Medicine.
Sources
- University of Texas Health Science Center at Houston, news release, Oct. 21, 2024
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Sexual Assault Triples Suicide Risk Among Veterans
WEDNESDAY, April 30, 2025 -- Sexual assault and sexual harassment during military service dramatically increases veterans’ risk of suicide later in life, a new study...
Fathers' Depression Affects Kids' Future Behavior
TUESDAY, April 29, 2025 — Dads are supposed to be strong, steady and stoic, given how they’re portrayed in sitcoms and family entertainment. But in real life, fathers...
FDA Warns of Unapproved Hair-Loss Product Linked to Side Effects
THURSDAY, April 24, 2025 — A quick spray of medication might seem like an easy way to get thicker hair, but some people say one sold online has left them battling sexual...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.